Table 2.
Comparison of outcomes measures before and after treatment with vitamin B12
| Variable | Before treatment | After treatment | Mean diff (95%C.I.) | p value |
|---|---|---|---|---|
| FIQR-total score | 49.80 (21.86) | 40.00 (18.36) | − 9.79 (− 4.13, − 15.45) | < 0.01 |
| FIQR-function domain | 13.17 (7.33) | 10.30 (5.84) | − 2.86 (− 0.53, − 5.20) | 0.01 |
| FIQR-overall domain | 10.32 (6.22) | 8.25 (6.22) | − 2.07 (− 0.20, − 3.93) | 0.03 |
| FIQR-symptom domain | 26.30 (10.39) | 21.44 (8.58) | − 4.85 (− 1.91, − 7.79) | < 0.01 |
| HADS-anxiety | 9.33 (4.30) | 7.70 (3.60) | − 1.63 (− 0.35, − 2.90) | 0.01 |
| HADS-depression | 6.67 (3.90) | 7.17 (3.76) | 0.50 (1.60, − 0.60) | 0.36 |
| SF12-physical component | 33.30 (10.22) | 36.90 (12.30) | − 3.28 (9.56) | 0.08 |
| SF12-mental component | 42.58 (14.70) | 43.82 (14.39) | − 1.24 (10.15) | 0.94 |
| Pain-VAS | 6.01 (2.68) | 5.45 (2.71) | − 0.58 (− 1.51, 0.35) | 0.21 |
Values are mean (standard deviation), FIQR revised fibromyalgia impact questionnaire, HADS hospital anxiety and depression scale, SF12 12-item short form survey, VAS visual analog scale
p value < 0.05 is statistically significant